Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505569 · ClinicalTrials.gov registry record · NA
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01505569 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 44 participants.
The verdict
NCT01505569, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant. For solid tumors, if appropriate, disease specific radiation therapy at day +60. For CNS tumors, the conditioning regimen and autologous peripheral blood stem cell transplant will be given for 3 cycles.
Interventions
- DRUG Busulfan
- DRUG Mesna
- DRUG Etoposide
- DRUG Ifosfamide
- BIOLOGICAL G-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-10-20 |
| Est. Completion | 2024-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01505569
The ClinicalTrials.gov registry entry for NCT01505569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Busulfan is the first listed.
NCT01505569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01505569 about?
NCT01505569 is a clinical study titled "Auto Transplant for High Risk or Relapsed Solid or CNS Tumors". This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant....
What is the current status of trial NCT01505569?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2011-10-20. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT01505569?
The interventions under investigation include: Busulfan (DRUG), Mesna (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), G-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01505569?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.